DOI:10.2214/AJR.04.1068
AJR 2006; 186:1703-1706
© American Roentgen Ray Society
Percutaneous Cryotherapy of the Thorax: Safety Considerations for Complex Cases
Abraham Ahmed1 and
Peter Littrup2
1 Wayne State University School of Medicine, 540 East Canfield, Detroit, MI
48202.
2 Department of Radiology, Karmanos Cancer Institute and Wayne State University,
Detroit, MI 48201.
Received July 6, 2004;
accepted after revision August 8, 2005.
Address correspondence to A. Ahmed
(aahmed{at}med.wayne.edu).
Keywords: ablation chest CT technique percutaneous safety
Introduction
Percutaneous cryotherapy may have a wide range of anatomic and tumor
treatment options because of its low pain, good ice visualization, and
preservation of collagenous tissue architecture. Cryoablation was performed in
the liver, prostate, kidney, and breast with good outcomes
[1-4].
More recently, we showed it to be safe and feasible in the thorax
[5] with basic CT and
cryotherapy equipment. Reports involving endobronchial cryotherapy followed by
external beam radiation also suggest better local tumor control than radiation
alone [6]. We used current
cryotechnology with angled probes (Fig.
1A) that allow CT fluoroscopy, including novel safety techniques.
Five successful cryotherapy procedures were performed in two complex patients
with sarcoma metastases to the lung.

View larger version (19K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1A 28-year-old woman with two metastatic foci from synovial cell
sarcoma. Angled cryoprobe (A) was used during all procedures.
Unenhanced CT images before cryotherapy show paraesophageal mass
(perpendicular bidimensional measurement calipers coinciding with numbers
1 and 2, B) abutting posterior aspect of trachea (white
arrow) and esophagus (black arrow). Locally recurrent mass is
seen (C) in right posterior costophrenic angle (arrows).
|
|
Materials and Methods
The first patient was a 28-year-old woman diagnosed with thoracic
metastases from high-grade synovial sarcoma. Two separate masses involved the
left upper lobe adjacent to the esophagus and the right posterior chest
wall-diaphragmatic junction. One year after surgical resection, chemotherapy,
external radiation, and brachytherapy, the primary mass in the right posterior
hemithorax had recurred. Chest CT showed a 6.5 x 3-cm mass abutting the
reconstructed diaphragm, which involved the adjacent ribs and dome of the
liver (Fig. 1C). Both this and
the other 3-cm tumor in the left posterior paraesophageal region
(Fig. 1B) were positive on FDG
PET and were confirmed to be metastatic synovial sarcoma with a CT-guided
18-gauge core biopsy.

View larger version (96K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1C 28-year-old woman with two metastatic foci from synovial cell
sarcoma. Angled cryoprobe (A) was used during all procedures.
Unenhanced CT images before cryotherapy show paraesophageal mass
(perpendicular bidimensional measurement calipers coinciding with numbers
1 and 2, B) abutting posterior aspect of trachea (white
arrow) and esophagus (black arrow). Locally recurrent mass is
seen (C) in right posterior costophrenic angle (arrows).
|
|

View larger version (107K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1B 28-year-old woman with two metastatic foci from synovial cell
sarcoma. Angled cryoprobe (A) was used during all procedures.
Unenhanced CT images before cryotherapy show paraesophageal mass
(perpendicular bidimensional measurement calipers coinciding with numbers
1 and 2, B) abutting posterior aspect of trachea (white
arrow) and esophagus (black arrow). Locally recurrent mass is
seen (C) in right posterior costophrenic angle (arrows).
|
|
The second patient was a 39-year-old woman diagnosed with bilateral
pulmonary metastases from alveolar soft part sarcoma (ASPS). Initially a 3
x 3-cm right hilar mass showed faster progression than approximately
seven other tiny (< 1-cm) nodules. Five months after cryotherapy of her
first mass, a 3.5 x 3-cm left aortopulmonary window tumor and another 3
x 3-cm right lower lobe mass had distinctly increased in follow-up.
External beam radiation was not considered, and bilateral surgical resection
was declined. Two additional cryotherapy sessions were then performed.
All procedures and associated chart reviews were performed with approval by
our university's institutional review board, including patient informed
consent. A CT scanner (Somatom Plus 4, Siemens Medical Solutions) with the
CARE Vision fluoroscopy package was used for all five procedures. The
cryosurgical unit for all procedures was an argon gas-based system (Cryocare,
Endocare). General endotracheal anesthesia was used only for the procedure
involving the paraesophageal mass, and all other procedures used IV midazolam
and morphine sedation titrated to patient comfort. After liberal injection of
Xylocaine (2%), a 20-gauge 15-cm needle was first inserted in the center of
each mass using CT fluoroscopy. Two angled 2.4-mm (outer diameter) cryoprobes
with sharp tips were spaced no more than 2 cm apart (Figs.
2A,
2B, and
2C) and placed directly along a
course tandem to the 20-gauge needle in the periphery of the masses. (This
"bracketing" approach allows for approximately 1-cm freeze
ablation margins beyond all visible tumor margins)
[5]. Freezing cycles generally
lasted 10 min (15 min in the larger chest wall tumor to ensure adequate tumor
margin coverage) for the first freeze cycle, followed by a 10-min passive thaw
and a 10-min refreeze. An additional probe was placed during the thaw phase of
two procedures because visible ice could not be verified to cover all tumor
margins (Fig. 1F).

View larger version (88K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2A 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Cryotherapy CT images show right hilar mass being treated (A)
from anterior approach with cryoprobes bracketing mass (arrows) to
avoid posterior vascular structures. Aortopulmonary window (B) mass is
being treated from an anterior approach. Two cryoprobes (C) are seen
bracketing second right lower lobe mass (arrow) from posterolateral
approach.
|
|

View larger version (80K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2B 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Cryotherapy CT images show right hilar mass being treated (A)
from anterior approach with cryoprobes bracketing mass (arrows) to
avoid posterior vascular structures. Aortopulmonary window (B) mass is
being treated from an anterior approach. Two cryoprobes (C) are seen
bracketing second right lower lobe mass (arrow) from posterolateral
approach.
|
|

View larger version (78K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2C 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Cryotherapy CT images show right hilar mass being treated (A)
from anterior approach with cryoprobes bracketing mass (arrows) to
avoid posterior vascular structures. Aortopulmonary window (B) mass is
being treated from an anterior approach. Two cryoprobes (C) are seen
bracketing second right lower lobe mass (arrow) from posterolateral
approach.
|
|

View larger version (90K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1F 28-year-old woman with two metastatic foci from synovial cell
sarcoma. One of two urethral warming catheters (D) used for esophageal
protection. Postcryotherapy CT images are at same levels as in Figures
1A,
1B,
1C. Four hours after
cryotherapy (E) shows no enhancement of paraesophageal mass (black
arrowheads) (note margin of tumor "ghost") with surrounding
area of approximately 1-cm thick border of cryotherapy effect. Posterior wall
of trachea (white arrow) and esophagus (black arrow) are
seen. Immediate removal of cryotherapy probes (F) with air density is
seen in five tracks. Track is shown (white arrow) where additional
probe was placed during thaw cycle to assure thorough lateral coverage of
low-density ice (black arrows) extending well beyond underlying tumor
ghost (white arrowheads).
|
|
Novel safety techniques included a vasoconstriction cocktail for all
procedures consisting of 2-3 mL of unlabeled macroaggregated albumin with
dilute (1:50,000-100,000) epinephrine, followed by 3-10 mL (i.e., depending on
mass size) of 7.5% hypertonic saline with dilute epinephrine. For esophageal
protection in the first patient, two 1-cm coaxial urethral warming catheters
(Urethral Warmer, Endocare) (Fig.
1D) [7] were placed
in the esophagus beyond the level of the adjacent mass. The freeze protocol
was also modified during one procedure in the ASPS patient to protect the
recurrent laryngeal nerve coursing near the left anteroposterior window mass.
She was instructed to hum (vocalize) until she noted some hoarseness, then the
flow rate of the cryoprobes was reduced to 50% and stopped after 6 min during
the first freeze. She experienced similar increased hoarseness during the
second freeze but tolerated a full 8-min third freeze at 100% flow without
significant voice changes.

View larger version (75K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1D 28-year-old woman with two metastatic foci from synovial cell
sarcoma. One of two urethral warming catheters (D) used for esophageal
protection. Postcryotherapy CT images are at same levels as in Figures
1A,
1B,
1C. Four hours after
cryotherapy (E) shows no enhancement of paraesophageal mass (black
arrowheads) (note margin of tumor "ghost") with surrounding
area of approximately 1-cm thick border of cryotherapy effect. Posterior wall
of trachea (white arrow) and esophagus (black arrow) are
seen. Immediate removal of cryotherapy probes (F) with air density is
seen in five tracks. Track is shown (white arrow) where additional
probe was placed during thaw cycle to assure thorough lateral coverage of
low-density ice (black arrows) extending well beyond underlying tumor
ghost (white arrowheads).
|
|

View larger version (88K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 1E 28-year-old woman with two metastatic foci from synovial cell
sarcoma. One of two urethral warming catheters (D) used for esophageal
protection. Postcryotherapy CT images are at same levels as in Figures
1A,
1B,
1C. Four hours after
cryotherapy (E) shows no enhancement of paraesophageal mass (black
arrowheads) (note margin of tumor "ghost") with surrounding
area of approximately 1-cm thick border of cryotherapy effect. Posterior wall
of trachea (white arrow) and esophagus (black arrow) are
seen. Immediate removal of cryotherapy probes (F) with air density is
seen in five tracks. Track is shown (white arrow) where additional
probe was placed during thaw cycle to assure thorough lateral coverage of
low-density ice (black arrows) extending well beyond underlying tumor
ghost (white arrowheads).
|
|

View larger version (55K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2D 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Postcryotherapy CT images are at same levels as in Figures
2A,
2B,
2C. Near complete resolution
(D) of previous right hilar mass (arrow) is seen 9 months
postprocedure. Four-hour postcryotherapy CT (E) is seen with minimal
enhancement of hypervascular anteroposterior window mass (white
arrow) and minimal effusion (black arrow). Four hours after
cryotherapy (F) shows minimal lateral pneumothorax
(arrowheads), and perpendicular bidimensional calipers (i.e.,
coinciding with numbers 1 and 2) denote estimated margins of cryotherapy
effect approximately 1 cm beyond right lower lobe tumor margins (i.e., hazy
consolidation surrounding underlying smaller white mass, arrows).
|
|

View larger version (80K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2E 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Postcryotherapy CT images are at same levels as in Figures
2A,
2B,
2C. Near complete resolution
(D) of previous right hilar mass (arrow) is seen 9 months
postprocedure. Four-hour postcryotherapy CT (E) is seen with minimal
enhancement of hypervascular anteroposterior window mass (white
arrow) and minimal effusion (black arrow). Four hours after
cryotherapy (F) shows minimal lateral pneumothorax
(arrowheads), and perpendicular bidimensional calipers (i.e.,
coinciding with numbers 1 and 2) denote estimated margins of cryotherapy
effect approximately 1 cm beyond right lower lobe tumor margins (i.e., hazy
consolidation surrounding underlying smaller white mass, arrows).
|
|

View larger version (86K):
[in this window]
[in a new window]
[as a PowerPoint slide]
|
Fig. 2F 39-year-old woman with three metastatic foci from alveolar soft part
sarcoma. Postcryotherapy CT images are at same levels as in Figures
2A,
2B,
2C. Near complete resolution
(D) of previous right hilar mass (arrow) is seen 9 months
postprocedure. Four-hour postcryotherapy CT (E) is seen with minimal
enhancement of hypervascular anteroposterior window mass (white
arrow) and minimal effusion (black arrow). Four hours after
cryotherapy (F) shows minimal lateral pneumothorax
(arrowheads), and perpendicular bidimensional calipers (i.e.,
coinciding with numbers 1 and 2) denote estimated margins of cryotherapy
effect approximately 1 cm beyond right lower lobe tumor margins (i.e., hazy
consolidation surrounding underlying smaller white mass, arrows).
|
|
Helical CT scans were performed immediately after an active thaw allowed
removal of cryoprobes less than 2 min after completion of the second freeze.
Follow-up chest CT scans were also performed approximately 4 hr after the
procedures to document any complications immediately before discharge.
Patients were called daily by a nurse coordinator to assess symptoms during
the first week postprocedure. Subsequent CT scans were scheduled at 1, 3, 6,
and 12 months after cryotherapy.
Results
All procedures were well tolerated without significant complications (i.e.,
tiny pneumothorax and pleural effusion not requiring intervention). Minor
discomfort at the procedure site generally resolved within 48 hr. Follow-up of
the first patient is at over 1 year for both procedures, and the second
patient is over 3 months after her second procedure. The first patient's chest
CT 4 hr after both procedures showed thorough hypovascular cryotherapy effect
beyond the paraesophageal and chest wall mass margins (Figs.
1E and
1F).
The hoarseness the second patient experienced during the anteroposterior
window mass procedure persisted 1 week after the procedure and resolved at 1
month. During cryotherapy of the hilar and mediastinal tumors, back bleeding
from the 20-gauge placement needle occurred immediately after removal of the
stylet but stopped after the vasoconstriction cocktail. Follow-up CT in this
patient showed areas of cryotherapy effect extending beyond previous tumor
margins (Figs. 2E and
2F). Neither nodular
enhancement nor tissue vascularity was seen, suggesting complete ablation and
longer follow-up. The right lower lobe mass showed progressive resorption to
approximately 1 x 1.5 cm 9 months postprocedure without significant
adjacent parenchymal scarring (Fig.
2D).
Discussion
Percutaneous cryotherapy of lung masses is technically feasible and may be
a valuable treatment alternative when other treatments do not result in
sufficient local tumor control. We achieved our major treatment goals of near
real-time procedure visualization, patient acceptance with minimal sedation,
and preservation of underlying tissue architecture with minimal complications.
Use of angled probes allowed for CT gantry clearance and real-time imaging
during probe placement to minimize procedural morbidity near major
vasculature. In our first patient, urethral warming catheters
[7] most likely preserved the
endoluminal mucosa of the esophagus, preventing native mucosal bacteria from
spreading to the necrotic cryoablation zone and causing perforation and
possibly abscess. Our vasoconstrictive cocktail also appeared to assist
hemostasis, particularly in the highly vascular ASPS tumor. The cocktail used
macroaggregated albumin to create a gel-like matrix
[8] to better contain the
subsequent injection of a hypertonic saline-epinephrine solution, which is
reported to minimize bleeding in polypectomies
[9]. As an established safe
adjunct for highly vascular tumors, we believe this cocktail is helpful, but
routine use requires further evaluation. In summary, complex cryotherapy
procedures are possible for nearly any location in the thorax if the
appropriate safety precautions embodied in our suggested techniques are
used.
References
- Lee FT Jr, Chosy SG, Littrup PJ, Warner TF, Kuhlman JE, Mahvi DM.
CT-monitored percutaneous cryoablation in a pig liver model: pilot study.
Radiology 1999;211
: 687-692[Abstract/Free Full Text]
- Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M.
Targeted cryoablation of the prostate: 7-year outcomes in the primary
treatment of prostate cancer. Urology2002; 60 [suppl 1]:3
-11[CrossRef][Medline]
- Collyer WC, Landman J, Olweny EO, et al. Comparison of renal
ablation with cryotherapy, dry radiofrequency, and saline augmented
radiofrequency in a porcine model. J Am Coll Surgery2001; 193:505
-513
- Littrup PJ, Freeman-Gibb L, Andea A, et al. Cryotherapy for breast
fibroadenomas. Radiology 2005;234
: 63-72[Abstract/Free Full Text]
- Wang H, Littrup PJ, Duan Y, Zhang Y, Feng H, Nie Z. Thoracic masses
treated with percutaneous cryotherapy: initial experience with more than 200
procedures. Radiology 2005;235
: 289-298[Abstract/Free Full Text]
- Vergnon JM, Schmitt T, Alamartine E, Barthelemy JC, Fournel P,
Emonot A. Initial combined cryotherapy and irradiation for unresectable
non-small cell lung cancer: preliminary results. Chest1992; 102:1436
-1440[Abstract/Free Full Text]
- Cohen JK, Miller RJ. Thermal protection of urethra during
cryosurgery of the prostate. Cryobiology1994; 31:313
-316[Medline]
- Order SE, Siegel JA, Principato R, et al. Selective tumor
irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a
phase I study. Int J Radiat Oncol Biol Phys1996; 36:1117
-1126[CrossRef][Medline]
- Shirai M, Nakamura T, Matsuura A, Ito Y, Kobayashi S. Safer
colonoscopic polypectomy with local submucosal injection of hypertonic
saline-epinephrine solution. Am J Gastroenterol1994; 89:334
-338[Medline]

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?